Accumulating evidence suggests that glioma stem cells (GSCs), which are rare cells characterized by pluripotency and self-renewal ability, are responsible for glioblastoma (GBM) propagation, recurrence and resistance to therapies. Bone morphogenic proteins (BMPs) induce GSC differentiation, which leads to elimination of GSCs and sensitization of glioma to chemotherapeutics. Alterations in the epidermal growth factor receptor (EGFR) gene are detected in more than half of GBMs; however, the role of EGFR in the chemoresistance of GSCs remains unknown. Here, we examined whether EGFR signaling affects BMP4-induced differentiation of GSCs and their response to the alkylating drug temozolomide (TMZ). We show that BMP4 triggers the SMAD signaling cascade in GSCs independent of the EGFR level. BMP4 downregulated the levels of pluripotency markers (SOX2 and OLIG2) with a concomitant induction of an astrocytic marker (GFAP) and a neuronal marker (β-Tubulin III). However, GSCs with different EGFR levels responded differently to treatments. BMP4-induced differentiation did not enhance sensitivity to TMZ in EGFRlow GSCs, in contrast to EGFRhigh GSCs, which underwent apoptosis. We then identified differences in cell cycle regulation. In EGFRlow cells, BMP4-triggered G1 cell cycle arrest which was not detected in EGFRhigh cells. RNA-seq profiles further highlighted transcriptomic alterations and distinct processes characterizing EGFR-dependent responses in the course of BMP4-induced differentiation. We found that the control of BIM (the pro-apoptotic BCL-2 family protein) by the AKT/FOXO3a axis only operated in BMP4-differentiated EGFRhigh cells upon TMZ treatment.
Glioblastoma (GBM; World Health Organization grade IV glioma) originates from neural stem or progenitor cells, when they undergo oncogenic transformation. GBMs show a high recurrence rate, and their resistance to therapy results in short patient survival, despite aggressive treatment including surgical resection, radiotherapy, and chemotherapy with temozolomide (TMZ). Antitumor efficacy of TMZ is limited by O6-methylguanine-DNA-methyltransferase (MGMT), a DNA repair protein. Methylation of the MGMT promoter reduces MGMT expression and its DNA repair activity and increases sensitivity to TMZ1,2. Out of dozens of genetic defects resulting in disrupted signaling pathways in GBMs, alterations in the epidermal growth factor receptor (EGFR) gene are frequent in GBMs3,4. The downstream target of EGFR signaling, the PI3K/AKT axis, controls cell survival and cell death by negatively regulating apoptosis and the expression of BCL2L11, encoding BIM (the pro-apoptotic protein from the BCL-2 family)5,6,7. AKT phosphorylates Forkhead box O (FOXO) transcription factors, including FOXO3a, which is subsequently exported from the nucleus to inhibit FOXO3a-dependent transcription. Inactivation of AKT leads to FOXO3a dephosphorylation, nuclear translocation, and transcription of target genes that regulate proliferation, differentiation, and apoptosis8. Thus, aberrations in EGFR signaling may limit programmed cell death initiated by therapeutics.
GBMs are highly heterogeneous tumors containing cells with distinct functional phenotypes and different molecular abnormalities9. Primary GBMs are either mono- or polygenomic tumors (64 versus 36%, respectively) and express glioma stem cell markers, including CD133, CD15, A2B5, and CD4410. The presence of glioma stem cells (GSCs) or tumor initiating cells confers intrinsic GBM heterogeneity11. GSCs have a great impact on glioma progression and treatment response, as the failure of current therapies to eliminate GSCs is considered to be a major factor contributing to inevitable GBM recurrence. Therapeutics specifically targeting GSCs are proposed as a promising treatment strategy. One such approach is to differentiate GSCs to reduce their intrinsic resistance12,13,14.
Several studies have demonstrated the differentiating potential of bone morphogenetic proteins (BMPs) in GBM-derived stem cells. BMP2- or BMP7-mediated differentiation makes tumor cells more sensitive to chemotherapeutics15,16. BMP4 was shown to induce GSC differentiation14,17, although detailed molecular mechanisms of BMP4-induced differentiation and improved response to chemotherapy need to be elucidated. BMP proteins bind as homodimers to a receptor complex composed of two BMP type 1 receptors (BMPR1A or BMPR1B class) and two type 2 receptors (BMPR2). Ligand binding and receptor kinase activation leads to phosphorylation of SMAD 1/5/8 proteins, which translocate into the nucleus in a complex with SMAD4 and activate transcription of genes involved in stem cell differentiation18,19,20. Exit from the cell cycle and arrest at the G0/G1 phase are prerequisites for cell differentiation21. Proteins from the BMP family trigger G1 arrest via induction of cyclin-dependent kinase inhibitor 1A (CDKN1A, p21CIP1) and cyclin-dependent kinase inhibitor 1B (CDKN1B, p27KIP1)22,23.
We hypothesized that the differentiation of GSCs with BMP4 would enhance their sensitivity to TMZ. We used four patient-derived GBMs to generate GSC-enriched, sphere cultures with different EGFR levels, and then we characterized the steps of BMP4-activated differentiation. We found significant differences in the outcomes of the treatment depending on EGFR expression, particularly in the cell cycle distribution and expression of cell cycle-related proteins. Using RNA-seq, we found transcriptomic differences and distinct processes that distinguish the responses of EGFRlow and EGFRhigh cells to BMP4-induced differentiation. The AKT/FOXO3a axis was an inducer of the pro-apoptotic protein BIM after TMZ treatment only in BMP4-differentiated EGFRhigh cells. The results pinpoint the importance of tumor genetic diagnostics to improve the response to therapies.
Materials and methods
Reagents and antibodies
Reagent and antibody sources were as follows: AG1478 (Calbiochem/Merck, Darmstadt, Germany), BMP4 (R&D Systems, Minneapolis, MN, USA), DAPI (4′,6-diamidino-2-phenylindole dihydrochloride), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), temozolomide (TMZ) and anti-β-Actin-peroxidase conjugated antibody (Sigma-Aldrich, Munich, Germany), anti-AKT, anti-phospho-AKT (Ser473), anti-phospho-AKT (Thr308), anti-BIM, anti-cleaved caspase 3, anti-cleaved caspase 7, anti-cleaved PARP (poly (ADP-ribose) polymerase-1), anti-EGF Receptor, anti-phospho-EGF receptor (Tyr1068), anti-FOXO3a, anti-phospho-FOXO3a (Thr32), anti-phospho-FOXO3a (Ser253), anti-phospho-FOXO3a (Ser318/321), anti-phospho-Rb (Ser807/811), anti-SMAD1, anti-SMAD3, anti-SMAD4, anti-SMAD5, anti-phospho-SMAD1/5 (Ser463/465), anti-phospho-SMAD3 (Ser423/425), anti-p27Kip1, anti-SOX2 (Cell Signaling Technology, Beverly MA, USA), anti-OLIG2, anti-β-Tubulin beta III isoform (Millipore, Temecula, CA, USA), anti-CYCLIN B1, p21CIP1 (Santa Cruz Biotechnology, Dallas, Texas, USA), anti-GFAP (BD Pharmingen San Jose, CA), anti-NESTIN (R&D Systems, Minneapolis, MN, USA), and anti-CYCLIN D1 (ThermoFisher Scientific, Waltham, MA USA).
Cell culture and differentiation induction
The L0125, L0512, L0615, and L0627 GBM GSC lines were provided by Dr Rossella Galli (San Raffaele Scientific Institute, Milan, Italy)24,25,26. For sphere forming assays, cells were seeded at a low density (3000 viable cells/cm2) onto nonadherent plates and cultured in DMEM/F-12 medium supplemented with 2% B27 (Gibco Invitrogen, Basel, Switzerland), 20 ng/ml rh bFGF (Miltenyi Biotec, Bergisch Gladbach, Germany), 20 ng/ml rh EGF (StemCell Technologies, Vancouver, BC, Canada), 0.0002% heparin (StemCell Technologies, Vancouver, BC, Canada), and antibiotics (Gibco Invitrogen, Basel, Switzerland). Cells were fed every 3 days by replacing 25% of the medium volume. After 6, 10, or 13 days of culturing, the spheres were collected by centrifugation at 110×g and then were lysed in Qiagen RLT lysis buffer for RNA isolation, lysed in buffer supplemented with complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA) for blotting, or the DNA was extracted.
For differentiation experiments, 6-day spheres were treated with 100 ng/ml BMP4 for 4 days with fresh BMP4 every 2 days. In some experiments, spheres were triturated to produce a single-cell suspension and then were seeded (2.5 × 104 viable cells/cm2) onto laminin-coated plates in the medium as described above. The next day after seeding, the cells were exposed to 100 ng/ml BMP4 for 4 days (fresh BMP4 was added every 2 days). After treatment, cells were fixed with 4% paraformaldehyde (PFA) for immunocytochemistry, or they were collected for RNA and protein extraction.
For cell viability evaluation, 2 days after seeding as described above, adherent cells were exposed to various concentrations of AG1478 (0.25–5 µM) for 3 days.
Control (maintained without treatment for 6 days) or BMP4-differentiated spheres/cells were treated with 500 µM TMZ or 1 µM AG1478 for 3 days. As DMSO induced the differentiation of embryonic stem cells27, for most experiments, TMZ was dissolved in deionized water. In some experiments, TMZ was dissolved in DMSO, and DMSO was used at corresponding concentrations. Sphere formation and the effect of drugs on cell morphology were monitored using an Olympus X70.
Whole cell lysates were prepared in a buffer containing phosphatase and protease inhibitors, and then they were separated by SDS-PAGE and transferred onto nitrocellulose membranes as described28,29. After blocking with 5% nonfat milk in a blocking buffer, the membranes were incubated overnight with primary antibodies and then with the appropriate secondary antibodies for 1 h. Immunocomplexes were visualized using an enhanced chemiluminescence detection system (SuperSignal West Pico PLUS, ThermoFisher Scientific, Waltham, MA, USA). The molecular weight of proteins was estimated with prestained protein markers (Sigma-Aldrich, Saint Louis, MO).
MTT metabolism test
Cell viability was evaluated using MTT metabolism tests, as previously described29. Briefly, upon cell treatment, MTT stock solution was added at a final concentration of 0.5 mg/ml. After 1 h of incubation at 37 °C, water-insoluble formazan was dissolved in DMSO. Optical densities were measured at 570 nm using a scanning multiwell spectrophotometer.
For cell cycle analysis, at least 0.5 × 106 cells were used. GBM cells were triturated to produce a single cell suspension, and then they were resuspended in ice-cold PBS and fixed in 70% ethanol overnight at −20 °C. After centrifugation, the cell pellet was washed with PBS and then incubated for 15 min in the dark in propidium iodide/RNase staining buffer (BD Pharmingen San Jose, CA). Cells (2000) were analyzed by flow cytometry.
Bisulfite DNA conversion and methylation-specific polymerase chain reaction (MS-PCR)
DNA was extracted using standard phenol/chloroform methods. The purity and concentration of DNA were estimated after collecting absorbance readings at 260/280 nm. DNA (2 μg) was treated with bisulfite (EpiTect Bisulfite Kit, Qiagen, Hilden, Germany). The modified DNA was amplified using primers specific for methylated or unmethylated MGMT gene promoters, as listed in Table S1. Each PCR mixture contained 1 μl of DNA, 500 nM of primers, 1x reaction buffer containing 1.5 mM MgCl2, and 1 U HotStarTaq DNA Polymerase and 250 mM dNTPs (Promega, USA). PCR was performed with thermal conditions as follows: 95 °C for 10 min, 45 cycles of 95 °C for 30 s, 57 °C for 30 s and 72 °C for 30 s with a final extension of 72 °C for 10 minutes. PCR products were visualized using 1.5% agarose gel, yielding a band of 81 bp for a methylated product and 93 bp for an unmethylated product. Positive methylated and positive unmethylated controls (EpiTect PCR Control DNA Set Qiagen, Hilden, Germany) were included.
Total RNA was extracted using an RNeasy Mini kit (Qiagen, Hilden, Germany) and purified using RNeasy columns. The integrity of RNA was determined using an Agilent 2100 Bioanalyzer. For qRT-PCR, total RNA from cells was used to synthesize cDNA by extension of oligo(dT)15 primers with SuperScript reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, USA). Real-time PCR experiments were performed in duplicate using a cDNA equivalent of 37.5 ng RNA in a 10-µl reaction volume containing 2x SYBR Green Fast PCR Master Mix (Applied Biosystems, Darmstadt, Germany) and a set of primers. SPP1 primers were from Qiagen (QT01008798, Hilden, Germany); sequences of other primers are listed in Table S1. Data were analyzed by the relative quantification method using StepOne Software (Applied Biosystems, Darmstadt, Germany). The expression of each product was normalized to that of 18S rRNA.
mRNA library preparation and sequencing
For transcriptome analysis, equivalent amounts of RNA were used. In total, 16 strand-specific polyA-enriched RNA libraries were prepared using a KAPA Stranded mRNA Sample Preparation Kit according to the manufacturer’s protocol (Kapa Biosystems, Wilmington MA, USA). Briefly, mRNA molecules were enriched from 50 to 250 ng of total RNA using poly-T oligo-attached magnetic beads (Kapa Biosystems). The obtained mRNA was subsequently fragmented, and first-strand cDNA was synthesized using reverse transcriptase and random hexamers. Subsequent cDNA synthesis was performed to generate double-stranded cDNA (dsDNA). Adenosines were added to the 3′ ends of dsDNA, and adapters were ligated (adapters from NEB, Ipswich, MA, USA). Following adapter ligation, uracil was digested by a USER enzyme from NEB (Ipswich, MA, USA) in a loop structure of the adapter. Adapters containing DNA fragments were amplified by PCR using NEB starters (Ipswich MA, USA). Library evaluation was performed with an Agilent 2100 Bioanalyzer using an Agilent DNA High Sensitivity chip (Agilent Technologies, Ltd.) The mean library size was 300 bp. Libraries were quantified using a Quantus fluorometer and QuantiFluor double-stranded DNA System (Promega). Libraries were run in a rapid run flow cell and were paired-end sequenced (2 × 76 bp) with a HiSeq 1500 system (Illumina, San Diego, CA, USA).
RNA-seq data alignment, processing, and analysis
The sequenced paired-end reads were mapped to the hg38 genome using tophat2 aligner v2.1.1 and the default parameters30. The expression estimates for each gene were obtained using the Bioconductor package edgeR31. TPM (transcripts per kilobase million) values were calculated and used to perform all visualizations and all analyses in addition to assessing differential expression. Genes that had significant (Benjamini and Hochberg-corrected P < 0.05) changes in their expression levels were identified as differentially expressed. The analyses of signaling pathways and transcription factor motifs were performed with enrichKEGG and GSEA functions, respectively, from the clusterProfiler32 Bioconductor package. The significance thresholds for the pathway and motif analyses were set to 0.01 and 0.05, respectively (Benjamini and Hochberg). To elucidate information about signal processing, only signaling pathways representing “Environmental Information Processing” and “Cellular Processes” in the KEGG database were analyzed. All gene ontology analyses were performed with the GO.db Bioconductor package and 0.01 significance threshold on Bonferroni corrected P-value (Fisher’s exact test). All statistical analyses were performed with R programming environment (http://r-project.org). The gene expression data can be downloaded from the NIH GEO database (GSE140441).
Statistical analysis of biochemical data
Data were analyzed by Student’s t-test or ANOVA with Duncan’s post hoc test using R programming environment.
BMP4 treatment triggers the differentiation of GBM-derived sphere cultures
To determine whether BMP4-induced differentiation modulates GSC resistance to temozolomide, we performed experiments as depicted in Fig. 1a. The experiments were performed using four GBM patient-derived GSC cultures with different levels of EGFR; the cultures were maintained in serum-free medium as floating spheres. L0125 and L0512 cells had low EGFR expression (EGFRlow), while L0615 and L0627 cells exhibited high EGFR levels (EGFRhigh). BMP4 treatment did not change the EGFR levels (Fig. 1b). The expression of BMP receptors was detected in all tested sphere cultures. The level of pathway-specific phospho-SMAD1/5, but not phospho-SMAD3, was increased upon BMP4 stimulation (Fig. S1). This indicates that BMP4 induces canonical BMP signaling in all tested GSCs and that different EGFR expression levels do not affect the SMAD signaling cascade (Fig. S1).
Upon BMP4 addition, most L0125 and L0627 cells showed signs of differentiation, and the cells became attached to the plates and flattened. L0615 spheres maintained their spherical shapes; however, the majority of spheres attached to the plates, and cells started to branch out (Fig. 1c). L0512 spheres were floating and maintained a spherical shape after BMP4 addition. The expression of pluripotency markers (SOX2, PROM1, OLIG2, and SPP1) significantly decreased in GSCs exposed to BMP4, with the exception of SOX2 and SPP1 (coding for osteopontin) in L0615 and L0125 sphere cultures, respectively (Fig. 1d). The expression of NESTIN (a marker of neural precursors) was significantly reduced only in L0512 and L0627 cells. Three out of four sphere cultures responded to BMP4 by increasing the mRNA levels of an astrocytic marker (glial fibrillary acidic protein, GFAP; Fig. 1d). The expression of a neuronal marker (β-Tubulin III, TUBB3) was not significantly increased by BMP4 treatment in L0125, L0512, and L0615 cells and was significantly downregulated in L0627 cells. However, western blot analysis indicated significant induction of β-Tubulin III in four cell lines, GFAP in three cell lines (except for L0512) and downregulation of OLIG2 and SOX2 in four cell lines (Fig. 1e, f). The expression of selected proteins remained unchanged in untreated sphere cultures maintained for 10 days, so the observed changes did not result from prolonged culturing (Ctrl 10 day, Fig. 1e, f). The most prominent effects were observed in BMP4-treated L0125 and L0615 GSCs; therefore, these two cell lines were used for global gene expression profiling.
Treatment with BMP4 impairs TMZ-induced cytotoxicity in EGFRlow cells but not in EGFRhigh cells
Using bisulfide methylation PCR, we found that L0125, L0512, and L0615 cells have both methylated and unmethylated MGMT gene promoters, whereas L0627 cells have only methylated promoters (Fig. S2a); therefore, L0627 cells should be more sensitive to TMZ. The cells were treated with TMZ for 72 h. We used TMZ dissolved in water, as the responses of GSCs to TMZ dissolved either in water or in DMSO were comparable (Fig. S2b–d). The analysis of the cell cycle and apoptotic hallmarks showed that independent of the solvent and MGMT status, TMZ-induced G2/M arrest and activation of the caspase cascade.
We tested whether BMP4-induced differentiation sensitizes GSCs to TMZ. Surprisingly, pretreatment with BMP4 did not increase the expression of apoptotic markers and even reduced the TMZ effect on EGFRlow cells (Fig. 2a, b), as demonstrated by significantly lower levels of cleaved PARP and cleaved Caspases 3 and 7. Upon BMP4 and TMZ treatments, there was a reduction in apoptosis markers in EGFRhigh cells compared to TMZ-treated cells, although possibly not to the same extent as what was observed in the EGFRlow cells (Fig. 2b). Because adherent GSCs are more frequently used for chemical screens than nonadherent GSCs33, we repeated the treatments using adherent GSC cultures. GSCs retained their stem properties for several days after adherence to the plates (data not shown). Adherent stem cells differentiated upon BMP4 exposure (Fig. S2e, f). However, even in adherent cultures, BMP4 treatment reduced sensitivity to TMZ in EGFRlow cells, in contrast to EGFRhigh cells, which underwent apoptosis (Fig. S2e–g). These findings suggest that differences in the responses of BMP4-differentiated GSCs to TMZ may be intrinsic and may be associated with EGFR levels.
To explain the observed differences in the cells, we performed RNA-seq analysis of EGFRlow (L0125) and EGFRhigh (L0615) spheres after BMP4- and/or TMZ- treatments. As both BMP4 and TMZ can influence the cell cycle, we compared the expression of genes involved in the cell cycle under the analyzed conditions (Fig. 2c). Using Gene Ontology (GO) annotations, we analyzed the expression changes of 916 genes grouped according to the ‘cell cycle’ GO term (GO:0007049). Their expression was different between EGFRlow and EGFRhigh cells upon BMP4/TMZ treatment. Unsupervised clustering of the analyzed genes distinguished two main clusters. Treatment of BMP4-differentiated EGFRlow cells with TMZ did not change the expression of genes involved in the G2/M phase (cluster 2 on Fig. 2c, Pv = 0.977), while BMP4-differentiated EGFRhigh cells showed increased expression of these genes after TMZ treatment (Fig. 2c, Pv = 0.038). This suggests that differences between EGFRlow (L0125) versus EGFRhigh (L0615) cells in the cell cycle arrest were triggered by TMZ after BMP4-induced differentiation.
Flow cytometry analysis of the cell cycle phases revealed significant shifts between cell cycle phases in EGFRlow and EGFRhigh cells after TMZ and/or BMP4 treatments (Fig. 2d, left panels). In EGFRlow cells, BMP4 treatment led to a significant increase in the number of cells in the G1 phase and a decrease in the number of cells in the G2/M phase (Fig. 2d, right panel). A decrease in the number of cells in G2/M phase was also observed after subsequent TMZ treatment (Fig. 2d, bottom right panel). In contrast, BMP4 treatment did not cause such changes in the cell cycle phase distribution in EGFRhigh cells.
Furthermore, we analyzed the levels of cell cycle regulatory proteins, such as phospho-Rb (retinoblastoma), cyclin B1, cyclin D1, and two cyclin-dependent kinase inhibitors, p21CIP1 and p27KIP1 (Fig. 2e, f). Immunoblot analysis showed that p21CIP1 accumulated after BMP4, TMZ, and combined treatment. The highest level of p21CIP1 was detected in cells treated with TMZ alone, with the exception of L0627 cells, where a decreased level of p21CIP1 was observed. Accumulation of cyclin B1 was prominent in cells exposed to TMZ, which is consistent with G2/M arrest. Treatment with BMP4 significantly reduced the level of cyclin B1 (Fig. 2e). On the other hand, in three out of four GSC cultures, we found accumulation of cyclin D1 and p27KIP1 and reduction of phospho-Rb (Ser 807/811) after BMP4 treatment, indicating cell cycle arrest at the G0/G1 phase. In all cells in which phospho-Rb levels were detectable, BMP4 treatment significantly decreased the phospho-Rb level. However, the results of the combined treatment were different depending on EGFR signaling. Compared to TMZ treatment alone, the combined treatment did not affect phospho-Rb levels in EGFRlow cells, while in EGFRhigh L0615 cells, a less prominent reduction in phospho-Rb was observed. In L0627 EGFRhigh cells, the phospho-Rb levels did not increase under any condition, which suggests more complex regulation in those cells (Fig. 2e, f). These findings are in accord with the results of transcriptomic and flow cytometry analyses. We conclude that BMP4 treatment of GSCs triggers cell cycle arrest, but the outcome may be influenced by EGFR status.
EGFR signaling affects BMP4-mediated differentiation
To characterize molecular events in BMP4-differentiated EGFRlow and EGFRhigh GSCs, we performed global gene expression profiling. First, we identified differentially expressed genes (DEGs) between untreated and BMP4-treated cells. BMP4 treatment caused greater transcriptomic changes in EGFRlow cells than it did in EGFRhigh cells (Fig. 3a, left panel). In both cell types, more genes were downregulated than upregulated. The majority of genes downregulated in EGFRhigh cells were also downregulated in EGFRlow (~71%). For upregulated genes, the similarity was less pronounced; only 59% of genes upregulated in EGFRhigh were also upregulated in EGFRlow spheres (Fig. 3b). We used a scatterplot to directly compare changes in the expression levels of the identified DEGs (Fig. 3c). The fold changes of the expression of downregulated genes were more similar between cell types than the fold changes of upregulated genes. These results suggest that BMP4 differentiation causes broader expression changes in EGFRlow spheres, and downregulated processes in EGFRlow and EGFRhigh cells are more similar than the upregulated ones.
To recognize functional processes modified by BMP4 treatment, we performed analysis of signaling pathways defined by Kyoto Encyclopedia of Genes and Genomes (KEGG, see methods for details). Interestingly, BMP4-triggered differentiation led to downregulation of the same signaling pathways in L0125 and L0615 glioma spheres (Fig. 3d, e). The strongest downregulation was observed in a pathway describing the cell cycle, confirming the findings presented above (Fig. 3e). Gene Ontology (GO) analysis supported these results. The top GO terms enriched in downregulated genes included DNA replication and mitotic division (Fig. S3a, b). These results reflect the inhibition of cell proliferation and again highlight that BMP4 triggered the differentiation of GSCs. On the other hand, the KEGG pathways enriched in upregulated DEGs provided a clear distinction between EGFRlow and EGFRhigh cells (Fig. 3f). In accordance with our biochemical results (Fig. 1e, f), BMP4 activates elements of the TGF-β pathway in both EGFRlow and EGFRhigh spheres. Additionally, a signaling pathway regulating the pluripotency of stem cells, which forms a part of the TGF-β pathway, was activated in both types of spheres. However, we observed that in EGFRhigh spheres but not in EGFGlow spheres, BMP4-induced differentiation was sufficient to activate genes in the apoptotic pathway (Figs. 3f and S3c).
This result was supported by Gene Set Enrichment Analysis (GSEA) of transcription factor (TF) binding motifs. We identified several TFs that may be associated with the diverse response of GSCs to BMP4. Among TFs potentially involved in BMP4-induced upregulation in EGFRhigh spheres but not in EGFRlow spheres, we identified FOXO3 (Fig. 3g). This protein can be regulated by EGFR signaling and triggers BIM-mediated apoptosis34. Therefore, we looked in greater depth at the genes involved in apoptotic pathways and differentially expressed after BMP4 treatment in at least one of the cell types. A vast majority of the selected genes showed the same expression profile between EGFRlow and EGFRhigh cells (Fig. 3h). However, 5 genes, namely, PIK3R3, MAPK10, CASP8, MAP3K14, and BCL2L11 (encoding BIM protein), were upregulated in EGFRhigh cells and downregulated in EGFRlow cells.
The differences between BMP4-triggered differentiation in EGFRlow and EGFRhigh cells were confirmed when the corresponding expression profiles were compared (Fig. 3i). In EGFRhigh differentiated cells, we observed upregulation of genes grouped into a cell cycle pathway (adj. Pv = 0.0017). We also observed differential activation of focal adhesion (adj. Pv = 0.0029) and Hippo signaling pathway genes (adj. Pv = 0.0029), which were upregulated when compared to untreated cells. Additionally, we found stronger activation of cellular senescence signaling in EGFRlow cells than in EGFRhigh cells (Fig. 3i, adj. Pv = 0.0013).
BMP4 and TMZ activate the AKT/FOXO3a/BIM axis in an EGFR-dependent manner
We compared the expression of BCL2L11, FOXO3, and AKT1 in untreated cells (Fig. 4a) and found that neither AKT1 nor BCL2L11 showed differential expression. Only FOXO3 was significantly upregulated in EGFRhigh GSCs. Additionally, some differences in the levels of phosphorylated proteins were observed (Fig. 4b). However, BMP4 and TMZ treatments triggered distinct regulation of the AKT/FOXO3a/BIM proteins (Figs. 4c and S4a, b). BMP4 treatment did not significantly diminish the levels of AKT or FOXO3a phosphorylation in EGFRlow cells (Fig. 4d), and it did not increase phospho-FOXO3a (Ser318) levels (Fig. S4b). At the same time, in EGFRhigh spheres, the levels of phosphorylated AKT (Thr308) and phosphorylated FOXO3a (Thr32) were significantly reduced (Fig. 4d). This was supported by enhanced levels of total AKT and FOXO3a after BMP4 treatment (Figs. 4d, S4a).
The changes in the mRNA and protein levels of BCL2L11/BIM corroborated our previous observations. The treatments led to significantly different regulation of the BCL2L11 gene in the analyzed GSCs (Fig. 4e). The BIM level was significantly higher in BMP4-differentiated and TMZ-treated EGFRhigh cells than it was in untreated cells or cells treated with TMZ alone (Fig. 4f). This suggests that inhibition of the AKT/FOXO3a axis leads to the preferential accumulation of BIM in EGFRhigh cells (Fig. 4d, f). TMZ did not affect the expression of BCL2L11 or the BIM protein level in BMP4-differentiated or undifferentiated EGFRlow cells (Fig. 4e, f). Similar changes in the AKT/FOXO3a/BIM pathway were observed in EGFRlow L0512 and EGFRhigh L0627 cells (Fig. S4c, d). This result was in agreement with the analysis of the levels of biochemical markers of apoptosis, such cleaved Caspases and cleaved PARP (Fig. 2a, b).
To explore the contribution of EGFR signaling to the observed events, the effects of pharmacological inhibition of EGFR on the TMZ response of BMP4-differentiated cells were analyzed (Fig. S4e–g). AG1478 (EGFR tyrosine kinase inhibitor) efficiently blocked EGFR activation solely in EGFRhigh cells (L0615 and L0627), as shown by a reduction in phospho-EGFR levels (Fig. S4e). Consistently, decreases in cell survival were observed only in EGFRhigh cells exposed to AG1478 (Fig. S4f). Treatment with 1 µM AG1478 did not affect the downstream signaling pathways involving phospho-AKT and phospho-FOXO3a (Fig. S4g) and did not augment the expression of apoptotic markers in comparison to what was observed in BMP4 and TMZ treatments, as revealed by analysis of cleaved Caspases, cleaved PARP and BIM. The accumulation of BIM and cleaved PARP in L0615 cells upon treatment with AG1478 suggests that these cells are more sensitive to the EGFR inhibitor than the other cells tested (Fig. S4g).
Together, these findings indicate that functionality of the BIM-related apoptotic axis in BMP4-differentiated GSCs is triggered by TMZ but can be modified by signaling proteins downstream of EGFR (Fig. 4g).
Glioma stem cells form a rare cell population within a tumor, and their resistance to treatment contributes to tumor recurrence35,36. Patient-derived GSCs cultured as spheres reproduce the genetic and phenotypic characteristics of GBM more faithfully than established glioma cell lines37. In this study, for the first time, we explored whether EGFR signaling has an impact on the responses of differentiated GSCs to temozolomide, a drug of choice in glioblastoma therapy. We found that BMP4 treatment induces the differentiation of GSCs regardless of their EGFR status (Fig. 1), which is in line with recent reports14. BMP4 reduced the stemness features of GSC spheres and induced the expression of differentiation markers. Differences in the pattern of markers and degree of differentiation could be due to epigenetic characteristics of the individual tumor38 or secretion of BMP antagonists, which may determine responses of GSCs to differentiation-inducing agents39,40. Additionally, increased activity or levels of SOX transcription factors may limit differentiation commitment13.
Components of the BMP signaling pathway were expressed in four GSC sphere cultures, and their activation was independent of EGFR levels (Figs. 1 and S1). Different BMPs have been shown to deplete the GSC population without inducing cell death14,41. We found that BMP4 did not induce apoptosis in GSCs; it increased the number of EGFRlow GSCs in the G1 phase and decreased those in the G2/M phase (Fig. 2a–d). BMP4 treatment did not cause significant changes in the cell cycle phase distribution in EGFRhigh GSCs (Fig. 2d). Carèn et al.13 reported that EGF/FGF signaling in GSCs differentiated with BMPs may trigger re-entry into the cell cycle. EGFR triggers downstream signaling pathways such as PI3K/AKT and Ras/Raf/MEK, which stimulate mitosis42. EGFR activation promotes glioma cell proliferation43, which may explain differences in the cell cycle arrest observed in cells with various EGFR levels. However, accumulation of two cyclin-dependent kinase inhibitors, p21CIP1 and p27KIP1, with concomitant reduction of phospho-Rb, was found in both cell types (Fig. 2e, f). The recognized differences in the expression of genes and proteins involved in cell cycle regulation were confirmed by genome-wide transcriptomic analysis (Fig. 2c). Interestingly, we found stronger activation of cellular senescence signaling in EGFRlow cells than we did in EGFRhigh cells (Fig. 3i).
BMP2 and BMP7 have been shown to induce the differentiation of GBM-derived stem cells and to sensitize cells to TMZ15,16. Herein, we found that pretreatment with BMP4 did not enhance sensitivity to TMZ in EGFRlow GSCs, but BMP4-differentiated EGFRhigh GSCs maintained the ability to undergo apoptosis (Fig. 2a, b). Sachdeva et al.44 reported that BMP pathway activation mediates GSC quiescence and confers resistance to radiation and TMZ chemotherapy. Although the status of EGFR was not analyzed, the effect of BMP4 on glioma cells was mediated by its downstream targets, p21CIP1 and ID1 (DNA-binding protein inhibitor 1).
The responses of different GSCs to TMZ could be variable for multiple reasons. It has been reported that GSCs derived from distinct tumor areas respond differently to TMZ. The cells from the inner portions of the GBM mass were more resistant to TMZ because of the high MGMT expression15,45. BMPs can sensitize GSCs to TMZ by affecting HIF1α stability and MGMT expression15,16. We demonstrated that neither TMZ nor BMP4 affected MGMT gene expression in L0125 cells, and in L0615 cells, the MGMT level was undetectable (data not shown). In our study, three out of four cell lines contained methylated and unmethylated MGMT gene promoters; the MGMT promoter in L0627 cells was found to be methylated (Fig. S2a), which was in accordance with other studies46. MGMT status had no impact on the responses of BMP4-differentiated EGFRlow and EGFRhigh GSCs to TMZ.
Global transcriptomic analysis revealed that while BMP4 downregulated genes did not depend on EGFR expression, the genes and processes activated after BMP4 stimulation differed between EGFRhigh and EGFRlow cells. Specifically, we found that AKT/FOXO3a/BIM signaling was differentially regulated in EGFRhigh and EGFRlow GSCs after the combined treatment (Figs. 3, 4). The high level of AKT-dependent signaling in EGFRhigh cells was independent of PTEN (phosphatase and tensin homolog deleted on chromosome 10) status, as described26. Several studies have reported that FOXO factors can initiate apoptosis by activating the transcription of FasL, coding for a ligand for the Fas-dependent cell death pathway, or BIM, a pro-apoptotic Bcl-2 family member47. BIM, as an activator BH3-only protein, binds to mitochondrial membranes and increases their affinity for pore-formers (e.g., BAX and BAK), which instigates mitochondria-dependent events such as the release of cytochrome c and other apoptotic factors48. Based on our findings, we assumed that TMZ induces BIM-dependent apoptosis in BMP4-differentiated EGFRhigh GSCs. Intriguingly, we observed the proapoptotic effect of TMZ on undifferentiated GSCs; however, upon BMP4 differentiation, only EGFRhigh cells responded in such a manner. One explanation could be that BMP4-induced G1 cell cycle arrest and resulting cellular senescence may lead to chemoresistance to TMZ in EGFRlow cells. In contrast, in EGFRhigh GSCs, EGFR signaling caused re-entry of differentiated cells into the cell cycle. Actively proliferating cells are more prone to DNA damage-triggered cell death induced by alkylating agents such as TMZ. FOXO3a has been shown to cooperate with SMAD2/3 and mediate BIM upregulation and apoptosis in hepatocarcinoma cells upon TGF-β-stimulation49.
Our findings are of clinical importance and may explain failures of TMZ therapy in some GBM patients. EGFRhigh GSCs are characterized by enhanced tumorigenic potential and highly invasive behavior, while EGFRlow GSCs form tumors with low efficiency and need to upregulate EGFR to be tumorigenic26. Gene expression profiling revealed that pro-invasive and angiogenic genes were overexpressed in xenografts derived from cells with high or low EGFR expression, respectively26. Interestingly, in EGFRlow cells, we found activation of the apelin signaling pathway, which is implicated in angiogenesis50,51. GSCs with different EGFR statuses responded differently to pharmacologic inhibition of EGFR26.
AG1478 (a specific EGFR tyrosine kinase inhibitor) efficiently reduced EGFR activation in EGFRhigh GSCs, but downstream PI3K-AKT signaling pathways were not affected. Treatment with AG1478 reduced the growth of EGFRhigh cells, although there was no activation of Caspases (Fig. S4e–g), which indicates that AG1478 reduced cell proliferation and induced cell cycle arrest in the G1 phase, as reported elsewhere52. In fact, several agents (antibodies as well as small molecules) targeting EGFR in glioblastomas have already been tested in patients, but targeting EGFR has not provided therapeutic benefits53,54. This could explain the lack of impact of AG1478 treatment on TMZ-induced apoptosis in EGFRhigh BMP4-differentiated cells, for which the downregulation of AKT is crucial. The EGFR-independent pathway may maintain stimulation of the PI3K-AKT signaling pathway. We and others previously reported an impact of integrin or JAK signaling in glioma intracellular signaling55,56, and other receptor tyrosine kinases57,58,59,60 may be involved. Clark et al.57 demonstrated a compensatory activation of EGFR-related family members (ERBB2 and ERBB3) that enabled glioma stem cell proliferation, suggesting that simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy. Other studies demonstrated that repression of AKT signaling and induction of apoptosis required concurrent inhibition of both EGFR and InsR (insulin receptor)/IGF-1R (insulin-like growth factor-1 receptor) signaling. Combining gefitinib (a specific EGFR inhibitor) and OSI-906 (a dual inhibitor of InsR/IGF-1R) was more effective than either agent alone in the inhibition of subcutaneous glioblastoma xenografts58. Tumors can evade EGFR inhibition through the upregulation and phosphorylation of MET tyrosine kinase receptor59 and by activation of the FGFR (fibroblast growth factor receptor)-ERK (extracellular signal-regulated kinases)-SPRY2 (Sprouty 2) signaling axis60. This dynamic rewiring of signaling processes that is observed in glioma cells could explain our failure in the inhibition of key downstream EGFR signaling components, such as AKT and FOXO3a, after using AG1478.
Several obstacles and failures of BMP-induced differentiation therapy for GBM have been recently reported51. Our findings help to comprehend why BMP-induced differentiation of GSCs does not improve therapeutic efficacy and why such therapy should be used with caution, especially for GBMs with low expression of EGFR. In summary, our results demonstrate that enhanced EGFR signaling causes re-entry of BMP4-differentiated EGFRhigh GSCs into the cell cycle, and only in such cells does TMZ trigger BIM-dependent apoptosis. This result is accomplished through reduction of PI3K/AKT signaling and activation of the FOXO3a/BIM axis, which is inactivated in EGFRlow cells. Our findings support the idea of evaluating the EGFR status in GSCs when choosing therapeutic strategies aimed at eliminating cancer stem cells.
Hegi, M. E. et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26, 4189–4199 (2008).
Jacinto, F. V. & Esteller, M. MGMT hypermethylation: A prognostic foe, a predictive friend. DNA Repair 6, 1155–1160 (2007).
Eskilsson, E. et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 20, 743–752 (2018).
Cancer, T. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
Gilley, J., Coffer, P. J. & Ham, J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J. Cell Biol. 162, 613–622 (2003).
Dijkers, P. F., Medema, R. H., Lammers, J.-W. J., Koenderman, L. & Coffer, P. J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 10, 1201–1204 (2000).
Sunters, A. et al. FoxO3a transcriptional regulation of bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278, 49795–49805 (2003).
Eijkelenboom, A. & Burgering, B. M. T. FOXOs: signalling integrators for homeostasis maintenance. Nat. Rev. Mol. Cell Biol. 14, 83–97 (2013).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
Stieber, D. et al. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol. 127, 203–219 (2014).
Dirkse, A. et al. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat. Commun. 10, 1–16 (2019).
Campos, B. et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin. Cancer Res. 16, 2715–2728 (2010).
Carén, H. et al. Glioblastoma stem cells respond to differentiation cues but fail to undergo commitment and terminal cell-cycle arrest. Stem Cell Rep. 5, 829–842 (2015).
Piccirillo, S. G. M. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761–765 (2006).
Persano, L. et al. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis. 3, e412 (2012).
Tso, J. L. et al. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol. Cancer 14, 1–17 (2015).
Watabe, T. & Miyazono, K. Roles of TGF-β family signaling in stem cell renewal and differentiation. Cell Res. 19, 103–115 (2009).
Miyazono, K., Kamiya, Y. & Morikawa, M. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 147, 35–51 (2010).
Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577–584 (2003).
Genander, M. et al. BMP signaling and its pSMADS1/5 target genes differentially regulate hair follicle stem cell lineages. Cell Stem Cell 15, 619–633 (2014).
Sherr, C. J. G1 phase progression: cycling on cue. Cell 79, 551–555 (1994).
Chang, S.-F. et al. BMP-4 induction of arrest and differentiation of osteoblast-like cells via p21 CIP1 and p27 KIP1 regulation. Mol. Endocrinol. 23, 1827–1838 (2009).
Wen, X.-Z., Miyake, S., Akiyama, Y. & Yuasa, Y. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem. Biophys. Res. Commun. 316, 100–106 (2004).
Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011–7021 (2004).
Di Tomaso, T. et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16, 800–813 (2010).
Mazzoleni, S. et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 70, 7500–7513 (2010).
Adler, S., Pellizzer, C., Paparella, M., Hartung, T. & Bremer, S. The effects of solvents on embryonic stem cell differentiation. Toxicol. Vitro 20, 265–271 (2006).
Ciechomska, I. A., Przanowski, P., Jackl, J., Wojtas, B. & Kaminska, B. BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells. Sci. Rep. 6, 38723 (2016).
Ciechomska, I. et al. Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells inin vitro andin vivo studies. Int. J. Cancer 117, 59–67 (2005).
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omi. J. Integr. Biol. https://doi.org/10.1089/omi.2011.0118 (2012).
Pollard, S. M. et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4, 568–580 (2009).
Liu, Z. et al. Piperlongumine-induced nuclear translocation of the FOXO3A transcription factor triggers BIM-mediated apoptosis in cancer cells. Biochem. Pharmacol. 163, 101–110 (2019).
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522–526 (2012).
Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391–403 (2006).
Lee, J. et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13, 69–80 (2008).
Walsh, D. W., Godson, C., Brazil, D. P. & Martin, F. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol. 20, 244–256 (2010).
Yan, K. et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 28, 1085–1100 (2014).
Chirasani, S. R. et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 133, 1961–1972 (2010).
Goffin, J. R. & Zbuk, K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin. Ther. 35, 1282–1303 (2013).
Yang, W. et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480, 118–122 (2011).
Sachdeva, R. et al. BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma. Sci. Rep. 9, 14569 (2019).
Pistollato, F. et al. Hypoxia and HIF1α repress the differentiative effects of BMPs in high-grade glioma. Stem Cells 27, 7–17 (2009).
Riccitelli, E. et al. Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. PLoS ONE 8, 1–11 (2013).
Carter, M. E. & Brunet, A. FOXO transcription factors. Curr. Biol. 17, R113–R114 (2007).
Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25, 65–80 (2018).
Zhao, X. et al. Threonine 32 (Thr32) of FoxO3 is critical for TGF-β-induced apoptosis via Bim in hepatocarcinoma cells. Protein Cell 6, 127–138 (2015).
Galanth, C., Hus-Citharel, A., Li, B. & Llorens-Cortes, C. Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr. Pharm. Des. 18, 789–798 (2012).
Carén, H., Beck, S. & Pollard, S. M. Differentiation therapy for glioblastoma – too many obstacles? Mol. Cell. Oncol. 3, e1124174 (2016).
Zhu, X. F. et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 169, 27–32 (2001).
Karpel-Massler, G., Schmidt, U., Unterberg, A. & Halatsch, M. E. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol. Cancer Res. 7, 1000–1012 (2009).
Hegi, M. E. et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - a phase II trial. Mol. Cancer Ther. 10, 1102–1112 (2011).
Swiatek-Machado, K. et al. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol. Ther. 13, 657–670 (2012).
Ellert-Miklaszewska, A., Poleszak, K., Pasierbinska, M. & Kaminska, B. Integrin signaling in glioma pathogenesis: From biology to therapy. Int. J. Mol. Sci. 21, 888 (2020).
Clark, P. A. et al. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia 14, 420–428 (2012).
Ma, Y. et al. InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma. Clin. Cancer Res. 22, 1767–1776 (2016).
Jun, H. J. et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 31, 3039–3050 (2012).
Day, E. K. et al. Glioblastoma cell resistance to EGFR and MET inhibition can be overcome via blockade of FGFR-SPRY2 bypass signaling. Cell Rep. 30, 3383–3396.e7 (2020).
The authors want to thank Karolina Stepniak, Agnieszka Kaczmarczyk, and Aleksandra Ellert-Miklaszewska for comments and discussion. JM was supported by the POLONEZ Fellowship of the National Science Centre in Poland 2016/23/P/NZ2/04111. This project was performed under the POLONEZ program, which has received funding from the European Union’s Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. 665778.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ciechomska, I.A., Gielniewski, B., Wojtas, B. et al. EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide. Exp Mol Med 52, 1326–1340 (2020). https://doi.org/10.1038/s12276-020-0479-9